Embolotherapy Market Reaches US$ 7.37 Billion by 2030

Embolotherapy Market Snapshot

“The global embolotherapy market was worth $3.89 billion in 2023 and is expected to be worth $7.37 billion by 2030, increasing at an 8.1% CAGR from 2023 to 2030.”

Embolotherapy is the process of obstructing arteries with a device (such as a balloon catheter) in order to treat or stop uncontrollable bleeding. Utilizing this technique, tumors are reduced and bleeding is controlled. It is an endovascular procedure that attempts to stop bleeding by restricting aberrant blood arteries.

Embolotherapy is mostly used to treat cervical uprooted pregnancy, postpartum situations, and pelvic tract hemorrhage. This treatment has shown promise in the management of iatrogenic solid organ, vascular, and non-operative organ damage, including lesions to the liver, spleen, and kidneys.

Embolotherapy is used to treat enlarged uterine fibroids, revascularize tissues, and organs prior to surgery, and eliminate duodenal varices. This necessitates choosing an embolization agent with the necessary level of vascular blockage permanence.

The rising incidence of hepatocellular cancer and liver cancer, along with the leading manufacturers' increased attention to technological breakthroughs, will drive up demand for embolotherapy. The market value for embolotherapy will expand as a result of rising infrastructure construction costs and improved research and development capabilities to advance healthcare technology.

Other factors influencing market expansion include rising personal disposable income and rising patient desire for minimally invasive procedures.

>>Download Sample Report Now: https://marketreportservice.com/reports/embolotherapy-market-54621 

What are the Impediments to the Global Embolotherapy Market?

The global embolotherapy market is impacted by various factors, including technological advancements, regulatory changes, and the need for improved patient care.

The global embolotherapy market faces challenges due to rigid regulatory rules, high costs, and a shortage of competent medical personnel. The market's growth is also hindered by the absence of negative effects associated with emboli-removal catheters, despite its numerous end-uses.

Market Trends

• The global market for embolotherapy is expected to grow due to the increasing incidence of liver cancer and the demand for minimally invasive techniques.
• The increasing number of patients suffering from hepatic cell carcinoma, varicose veins, renal cell carcinoma, and aneurysms is driving market expansion.
• Additionally, rising healthcare infrastructure investment and R&D efforts are expected to fuel this growth.

Embolotherapy Market Segment Analysis

On the basis of product embolotherapy market is subdivided into Embolic Agents and Support Devices. Also, Embolic Agents are further segmented into Microspheres, Embolic Coils Liquid Embolic Agents, Embolic, Plug Systems, and Detachable Balloons. And Support Devices are sub-segmented into Microcatheters and Guidewires.

In 2022, the microspheres subsegment of embolic agents retained the biggest market share. Microspheres are frequently used to treat hepatocellular carcinoma, which is one of the primary factors driving this market segment's expansion, along with favorable reimbursement standards in developed economies.

New product launches and approvals are also contributing to the expansion of this market category. While cyanoacrylate and ethylene vinyl alcohol are examples of liquid embolic agents. Cyanoacrylate is a liquid glue that, after being extruded from the catheter, solidifies when it comes into contact with blood.

Detachable balloons are used to occlude vessels, non-detachable balloons are used to temporarily occlude vessels (typically to determine whether obstructing a channel is safe before doing so permanently), and high-pressure angioplasty balloons are used to crush plaque during revascularization procedures.

 The segment support device is a mobile device that runs Android software and one or more versions of Android that are supported by the software together constitute a supported device. Support device contains Microcatheters and Guidewires. Microcatheters are used in order to reach distal anatomy, traverse lesions, deliver therapeutic emboli, inject contrast medium, and carry out other procedures during complex endovascular procedures, microcatheters, which have a 0.70-1.30mm diameter, are employed.

While Guidewires are used in order to navigate the circulatory system and reach the desired location, guidewires and catheters are employed during minimally invasive interventional treatments. The use of computer models to forecast how these devices would behave is growing.

Transcatheter Arterial Embolization (TAE), Selective Internal Radiation Therapy (SIRT), and Trans Arterial Chemoembolization (TACE) are the Procedures of the embolotherapy market.

Transcatheter Arterial Embolization (TAE) is a process that stops the blood flow to a tumor or other aberrant region of tissue. TAE involves making a tiny cut in the inner thigh to introduce a catheter (a thin, flexible tube) into an artery close to the tumor or aberrant tissue. And the SIRT is a multimodal therapy that combines oncology, interventional radiology, and nuclear medicine.

High doses of targeted internal radiation are delivered to the liver cancer tissues only, sparing the parenchyma of the normal liver that lies nearby. To treat liver cancer, a special form of chemoembolization known as trans Arterial chemoembolization (TACE) clogs the hepatic artery.

 A minimally invasive method called transcatheter arterial chemoembolization (TACE) is used in interventional radiology to cut off a tumor's blood supply. An artery directly supplying the tumor is selectively injected with small embolic particles coated with chemotherapy medicines using a catheter.

These particles assault the tumor in several ways by blocking the blood supply and inducing cytotoxicity. Tumors from liver cancer are capable of angiogenesis, the growth of new blood vessels. In interventional radiology, a type of radiation treatment called selective internal radiation therapy (SIRT), often referred to as trans Arterial radioembolization (TARE), radioembolization, or intra-arterial micro brachytherapy, is used to treat cancer.

It is often reserved for carefully chosen individuals with tumors that are surgically incurable, particularly hepatocellular carcinoma or liver metastases. The procedure includes injecting minute radioactive microspheres into the arteries feeding the tumor, where they lodge in the tumor's tiny blood channels.

This procedure is also known as radioembolization since it combines radiotherapy with embolization. Chemoembolization, of which transcatheter arterial chemoembolization (TACE) is the typical form, is the term used to describe the chemotherapy analog that combines chemotherapy with embolization.

Hospitals, Clinics, and Ambulatory Surgery Centers are the end-users of the Embolotherapy Market. The primary end users of embolotherapy equipment are hospitals and clinics. This market segment includes products used in critical care units, minor clinics, and large hospitals for embolotherapy.

The main factors that are anticipated to drive the demand for embolization devices in hospitals and clinics are the growing adoption of minimally invasive surgical procedures (including vascular, urological, and neurological procedures), increasing purchasing power of major healthcare providers across developed countries (due to the consolidation of healthcare providers), and the greater availability of reimbursements for target procedures in the US and major European countries.

Embolotherapy Market Competitors

The major Competitors operating in the global Embolotherapy industry include the major market players are Boston Scientific Corporation, Cook Medical, Guerbet, Imbiotechnologies Ltd., Johnson & Johnson, Kaneka Corporation, Medtronic, Meril Life Sciences Pvt. Ltd., Merit Medical Systems, Inc., Penumbra, Inc., Simbionix USA Corporation, Sirtex Medical Limited, Stryker Corporation and others.

New Developments

In June 2022 -Stryker, today the opening of its new research and development facility, Stryker’s Global Technology Centre (SGTC), at the International Tech Park. The 150,000-square-foot facility will help accelerate innovation in India and globally, and further support the company’s mission to make healthcare better.

Aug. 15, 2022 -Boston Scientific Corporation announced the acquisition of Obsidio, Inc., a privately-held company that has developed the Gel Embolic Material (GEM™) technology used for embolization of blood vessels in the peripheral vasculature.

19 January 2021: Sirtex acquired the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma.

12 February 2020: Sirtex Medical announced a collaboration with MIM Software Inc.

Embolotherapy Market Regional Outlook 

Due to the prevalence of favorable reimbursement rules and the presence of significant companies, North America dominates the embolotherapy industry. The prevalence of high-tech healthcare facilities will also fuel market expansion in this area.

The regional embolotherapy market will be driven by aggressive healthcare spending and a large global population of cardiovascular sufferers. With a 37% revenue share of the global embolotherapy market in 2022, North America currently dominates the industry.

The increased frequency of indications for embolization treatments, the region's well-established healthcare ecosystem, and the development of sophisticated embolic agents by firms doing business there are some of the primary factors propelling the growth of the North American market.

The American government has made large efforts to reduce the number of cancer cases, which has resulted in a decline in cancer incidence. The U.S. Preventive Services Task Force (USPSTF) and the U.S. Preventive Services Board (USPSB) routinely assess the efficacy of clinical prevention services in-depth.

Europe is projected to be the second-leading region in the embolotherapy market, with an 8.0% CAGR. This growth is driven by rising cancer rates, availability of therapy, and health awareness. The prevalence of cardiovascular diseases in European countries like the UK, Germany, and Italy is expected to drive the industry, while well-established payment systems are crucial for its adoption.

Segments Covered in the Embolotherapy Market

Embolotherapy Market by Product

Embolic Agents

• Microspheres
• Embolic Coils Liquid Embolic Agents
• Embolic Plug Systems
• Detachable Balloons

Support Devices

• Microcatheters
• Guidewires

Embolotherapy Market by Procedure

• Transcatheter Arterial Embolization (TAE)
• Selective Internal Radiation Therapy (SIRT)
• Trans Arterial Chemoembolization (TACE)

Embolotherapy Market by End-User

• Hospitals
• Clinics
• Ambulatory Surgery Centers

The above information has been provided for the following regions and countries

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Russia

Asia Pacific

• China
• India
• Japan
• South Korea

Latin America

• Brazil
• Mexico

MEA

• UAE
• Saudi Arabia
• South Africa

Frequently Asked Questions

What is the worth of the global embolotherapy market?

The global embolotherapy market was worth $3.89 billion in 2023 and is expected to be worth $7.37 billion by 2030, increasing at an 8.1% CAGR from 2023 to 2030.

Which market segments are covered in the report on the Embolotherapy market?

Based on product, Procedure, end-user, and region the embolotherapy market reports divisions are broken down.

What is the CAGR of the embolotherapy market?

The global embolotherapy market registered a CAGR of 8.1% from 2023 to 2030. The industry segment was the highest revenue contributor to the market.

Which are the top companies to hold the market share in the embolotherapy market?

Key players profiled in the report include Boston Scientific Corporation, Cook Medical, Guerbet, Imbiotechnologies Ltd., Johnson & Johnson, Kaneka Corporation, Medtronic, Meril Life Sciences Pvt. Ltd., Merit Medical Systems, Inc., Penumbra, Inc., Simbionix USA Corporation, Sirtex Medical Limited, Stryker Corporation and other

Which is the largest regional market for the Embolotherapy market?

North America dominates the embolotherapy market as a result of the prevalence of favorable reimbursement regulations and the presence of large players.